IL15 and ovarian carcinoma: The IL-15 super-agonist (ALT-803), a (N72D) IL-15/IL-15Rα/IgG1-Fc complex with potent agonist function to the CD122/CD132 dimers [139] and increased half-life [140] is currently being evaluated in clinical trials in ovarian cancer (NCT03054909), multiple myeloma (NCT02099539) and AML (NCT02989844) without any efficacy result published yet.